{"id":"W2080156752","doi":"10.1111/j.1525-1438.2005.00483.x","title":"A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer","year":2005,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC","funders":"University of Pittsburgh","keywords":"Medicine; Concomitant; Ovarian cancer; Internal medicine; Adjuvant; Chemotherapy; Adverse effect; Monoclonal antibody; Immune system; Antibody; Oncology; Immunotherapy; Phases of clinical research; Cancer; Gastroenterology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003053798,0.0002199815,0.000554963,0.0002213611,0.00005283327,0.00003566585,0.0003322306,0.00005190046,0.002972975],"category_scores_gemma":[0.0001172558,0.000155191,0.000211935,0.0001352603,0.00004101855,0.0001422398,0.00005398415,0.0002000398,0.000006389633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00108382,"about_ca_system_score_gemma":0.0004887481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005406723,"about_ca_topic_score_gemma":0.0008241039,"domain_scores_codex":[0.9978562,0.00006596507,0.0008255425,0.0002963773,0.0007091921,0.0002467408],"domain_scores_gemma":[0.997884,0.0001844281,0.0005054234,0.0001711769,0.001020949,0.0002340171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04094687,0.06137316,0.06816114,0.00005570231,0.006031996,0.0005394024,0.002026402,0.002253592,0.0111778,0.0006566248,0.002705688,0.8040716],"study_design_scores_gemma":[0.07644964,0.1317434,0.6744201,0.0007142419,0.001496968,0.0002848786,0.0005911387,0.0008307307,0.009254738,0.0003468857,0.1033281,0.0005392564],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845817,0.001706347,0.0002599283,0.01062576,0.001565522,0.001018373,0.0001298741,0.0000114585,0.0001010016],"genre_scores_gemma":[0.9935948,0.0008426803,0.001435926,0.002360113,0.001257193,0.0003175843,0.00001616444,0.00002354646,0.0001520193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8035324,"threshold_uncertainty_score":0.9979385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07371906642979087,"score_gpt":0.4565962377889497,"score_spread":0.3828771713591588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}